Compare SSL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSL | TGTX |
|---|---|---|
| Founded | 1950 | 1993 |
| Country | South Africa | United States |
| Employees | 27411 | 399 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.0B |
| IPO Year | N/A | 2008 |
| Metric | SSL | TGTX |
|---|---|---|
| Price | $13.51 | $39.46 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $49.80 |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 04-24-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | $3.79 | $49.08 |
| Revenue Next Year | $4.39 | $26.69 |
| P/E Ratio | ★ $13.51 | $340.88 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.90 | $25.37 |
| 52 Week High | $14.37 | $44.65 |
| Indicator | SSL | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 56.82 |
| Support Level | $11.82 | $33.05 |
| Resistance Level | $13.68 | $44.65 |
| Average True Range (ATR) | 0.33 | 1.94 |
| MACD | -0.09 | 0.16 |
| Stochastic Oscillator | 57.66 | 54.82 |
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: the Southern Africa Energy & Chemicals business and the International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business, which operates integrated value chains with feedstock sourced from the Mining and Gas operating segments. Geographically, the company generates the majority of its revenue from South Africa.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.